Compare Stocks

→ A new way to collect income from stocks (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLCM Bellicum Pharmaceuticals	$0.07 -6.6%	$0.08	$0.06 ▼ $1.31	$727K	1.39	22,874 shs	6,000 shs
DMAC DiaMedica Therapeutics	$2.53 +3.3%	$2.80	$1.53 ▼ $4.75	$96.03M	1.69	40,918 shs	6,852 shs
ITRM Iterum Therapeutics	$1.57 +1.3%	$1.51	$0.62 ▼ $2.50	$25.80M	2.36	501,690 shs	50,845 shs
VBLT Vascular Biogenics	$5.46 -8.8%	$0.40	$0.10 ▼ $6.74	$423.91M	0.77	2.19 million shs	161,505 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLCM Bellicum Pharmaceuticals	0.00%	0.00%	0.00%	-25.20%	-77.68%
DMAC DiaMedica Therapeutics	+1.24%	-5.77%	-8.58%	-8.58%	+60.13%
ITRM Iterum Therapeutics	-1.90%	+7.64%	0.00%	-6.63%	+51.22%
VBLT Vascular Biogenics	0.00%	0.00%	0.00%	0.00%	+3,207.09%

World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLCM Bellicum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	2.0428 of 5 stars	3.5	4.0	0.0	0.0	3.3	0.0	0.0
ITRM Iterum Therapeutics	1.2062 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.6
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLCM Bellicum Pharmaceuticals	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	3.00	Buy	$7.00	176.68% Upside
ITRM Iterum Therapeutics	3.00	Buy	$6.00	282.17% Upside
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest VBLT, ITRM, DMAC, and BLCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
4/1/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/21/2024	DMAC DiaMedica Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
3/21/2024	DMAC DiaMedica Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$7.00 ➝ $6.00
3/6/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
2/7/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$6.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLCM Bellicum Pharmaceuticals	$1.50M	0.48	N/A	N/A	$0.23 per share	0.33
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.48) per share	N/A
VBLT Vascular Biogenics	$660K	642.29	N/A	N/A	$0.32 per share	17.06

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLCM Bellicum Pharmaceuticals	-$24.97M	N/A	0.00	∞	N/A	N/A	N/A	-157.93%	N/A
DMAC DiaMedica Therapeutics	-$19.38M	-$0.62	N/A	∞	N/A	N/A	-40.07%	-37.90%	5/20/2024 (Estimated)
ITRM Iterum Therapeutics	-$38.37M	-$2.97	N/A	N/A	N/A	N/A	-664.00%	-87.64%	5/10/2024 (Estimated)
VBLT Vascular Biogenics	-$32.30M	-$0.21	N/A	∞	N/A	N/A	-73.45%	-54.11%	N/A

Latest VBLT, ITRM, DMAC, and BLCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/28/2024	Q4 2023	ITRM Iterum Therapeutics	-$1.02	-$0.94	+$0.08	-$0.94	N/A	N/A
3/20/2024	N/A	DMAC DiaMedica Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLCM Bellicum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLCM Bellicum Pharmaceuticals	N/A	3.04	3.04
DMAC DiaMedica Therapeutics	N/A	19.27	19.27
ITRM Iterum Therapeutics	3.63	1.89	1.89
VBLT Vascular Biogenics	N/A	4.63	4.63

Ownership

Institutional Ownership

Company	Institutional Ownership
BLCM Bellicum Pharmaceuticals	4.93%
DMAC DiaMedica Therapeutics	10.12%
ITRM Iterum Therapeutics	9.21%
VBLT Vascular Biogenics	0.96%

Insider Ownership

Company	Insider Ownership
BLCM Bellicum Pharmaceuticals	10.30%
DMAC DiaMedica Therapeutics	7.20%
ITRM Iterum Therapeutics	5.40%
VBLT Vascular Biogenics	6.13%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BLCM Bellicum Pharmaceuticals	13	9.72 million	8.72 million	Not Optionable
DMAC DiaMedica Therapeutics	18	37.96 million	35.23 million	Optionable
ITRM Iterum Therapeutics	14	16.43 million	15.54 million	Not Optionable
VBLT Vascular Biogenics	7	77.64 million	72.88 million	Optionable

VBLT, ITRM, DMAC, and BLCM Headlines

Source	Headline
	Tommy Garten elected to VBL Hall of Fame therecorderonline.com - March 28 at 1:31 PM
	Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system nature.com - February 21 at 3:29 PM
	Vascular News and Research news-medical.net - November 25 at 2:28 PM
	Vascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26 msn.com - November 3 at 12:39 AM
	Notable Labs Closes Merger Transaction With VBL Therapeutics finance.yahoo.com - October 16 at 3:55 PM
	VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting finance.yahoo.com - October 12 at 3:13 PM
	VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting finance.yahoo.com - October 4 at 8:40 AM
	Vascular Biogenics Rises on Presentation Hype finance.yahoo.com - September 9 at 12:00 PM
	VBLT Stock Sees Decline of Approximately -0.22% in Last Five Days knoxdaily.com - September 7 at 9:15 PM
	VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC finance.yahoo.com - September 6 at 7:30 PM
	VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT businesswire.com - August 28 at 7:00 PM
	VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT businesswire.com - August 28 at 3:04 PM
	VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - August 14 at 8:09 AM
	Monitoring Vascular Biogenics Ltd. (VBLT) after recent insider movements knoxdaily.com - July 26 at 4:10 PM
	Vascular Biogenics (NASDAQ: VBLT) fool.com - July 23 at 5:52 PM
	Recent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT) knoxdaily.com - July 12 at 4:20 PM
	VBLT Stock Sees Decline of Approximately -4.31% in Last Five Days knoxdaily.com - July 7 at 2:11 PM
	Days-to-cover ratio for VBLT surges to 0.84 due to rise in short interest knoxdaily.com - June 23 at 8:26 PM
	The Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgery medscape.com - May 18 at 1:35 AM
	VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 15 at 8:03 PM
	Developing a Patient-Centered Approach to Vascular Access Device Selection medscape.com - May 10 at 8:52 AM
	CADASIL: The Most Common Hereditary Subcortical Vascular Dementia medscape.com - May 5 at 1:05 AM
	Aspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Disease medscape.com - May 2 at 8:00 PM
	Vascular Biogenics Stock (NASDAQ:VBLT), Dividends benzinga.com - April 4 at 1:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bellicum Pharmaceuticals

NASDAQ:BLCM

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

DiaMedica Therapeutics

NASDAQ:DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Iterum Therapeutics

NASDAQ:ITRM

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Vascular Biogenics

NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial